INSIGHTS ON CLINICAL TRIAL TECHNOLOGIES

CLINICAL TRIAL TECHNOLOGY SOLUTIONS

  • What can 22,000 people with an AI-mindset accomplish?

    Speed without shortcuts

    AI in clinical development at Parexel enables our teams to surface predictive insights at every stage, reducing protocol risk, study delays, and costly trial amendments.

    Parexel's approach to AI in clinical development is built on the Precision Pathway, a strategic operating model that embeds AI across the full trial lifecycle. AI empowers our teams at critical decision points to:

    1. Simplify complex tasks to accelerate timelines: AI capabilities are delivering up to 50% cycle time reductions in IND submission generation.
    2. Apply insights with agility to enable better decision-making
    3. Enhance data handling to drive first-time quality through content generation and workflow automation
  • Trying to archive a TMF delivered by a CRO? Need out of non-compliant file systems? Interested in reducing archival costs? Discover how IQVIA eArchive could be the solution for these issues and more.

  • Learn how to adopt artificial intelligence in practical, measurable ways, from protocol feasibility and cohort modeling to clinical trial disclosure and transparency.

  • Explore an imaging library that empowers organizations to extract deeper insights, reduce inefficiencies, and drive innovation across the clinical research landscape.

  • Neither traditional nor hybrid clinical trials can operate on rigid EDC systems.

    They require flexible data collection systems that support protocol amendments without downtime and accept mobile data without hassle. As a cloud-native solution, TrialKit bends to accommodate mid-study changes. And as the first full-featured EDC platform available as a native mobile app, TrialKit flexes to meet the demands of traditional, hybrid/decentralized, and completely remote clinical trials.

    Give your team the freedom to build, deploy, and manage their studies, their way—weeks faster than with rigid EDCs and for a fraction of the cost of the major players.